This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Midthun, K.
Right arrow Articles by Kapikian, A. Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Midthun, K.
Right arrow Articles by Kapikian, A. Z.

 Previous Article

Clinical Microbiology Reviews, 07 1996, 423-434, Vol 9, No. 3
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Rotavirus vaccines: an overview

K Midthun and AZ Kapikian
Division of Vaccines and Related Products Application, Food and Drug Administration, Rockville, Maryland 20852, USA.

Rotavirus vaccine development has focused on the delivery of live attenuated rotavirus strains by the oral route. The initial "Jennerian" approach involving bovine (RIT4237, WC3) or rhesus (RRV) rotavirus vaccine candidates showed that these vaccines were safe, well tolerated, and immunogenic but induced highly variable rates of protection against rotavirus diarrhea. The goal of a rotavirus vaccine is to prevent severe illness that can lead to dehydration in infants and young children in both developed and developing countries. These studies led to the concept that a multivalent vaccine that represented each of the four epidemiologically important VP7 serotypes might be necessary to induce protection in young infants, the target population for vaccination. Human-animal rotavirus reassortants whose gene encoding VP7 was derived from their human rotavirus parent but whose remaining genes were derived from the animal rotavirus parent were developed as vaccine candidates. The greatest experience with a multivalent vaccine to date has been gained with the quadrivalent preparation containing RRV (VP7 serotype 3) and human-RRV reassortants of VP7 serotype 1, 2, and 4 specificity. Preliminary efficacy trial results in the United States have been promising, whereas a study in Peru has shown only limited protection. Human-bovine reassortant vaccines, including a candidate that contains the VP4 gene of a human rotavirus (VP4 serotype 1A), are also being studied.


This article has been cited by other articles:

  • Kiulia, N. M., Kamenwa, R., Irimu, G., Nyangao, J. O., Gatheru, Z., Nyachieo, A., Steele, A. D., Mwenda, J. M. (2008). The Epidemiology of Human Rotavirus Associated with Diarrhoea in Kenyan Children: A Review. J Trop Pediatr 54: 401-405 [Abstract] [Full Text]  
  • Dennehy, P. H. (2008). Rotavirus Vaccines: an Overview. Clin. Microbiol. Rev. 21: 198-208 [Abstract] [Full Text]  
  • Kaufhold, R. M., Field, J. A., Caulfield, M. J., Wang, S., Joseph, H., Wooters, M. A., Green, T., Clark, H. F., Krah, D., Smith, J. G. (2005). Memory T-Cell Response to Rotavirus Detected with a Gamma Interferon Enzyme-Linked Immunospot Assay. J. Virol. 79: 5684-5694 [Abstract] [Full Text]  
  • Sestak, K., McNeal, M. M., Choi, A., Cole, M. J., Ramesh, G., Alvarez, X., Aye, P. P., Bohm, R. P., Mohamadzadeh, M., Ward, R. L. (2004). Defining T-Cell-Mediated Immune Responses in Rotavirus-Infected Juvenile Rhesus Macaques. J. Virol. 78: 10258-10264 [Abstract] [Full Text]  
  • Silvestri, L. S., Taraporewala, Z. F., Patton, J. T. (2004). Rotavirus Replication: Plus-Sense Templates for Double-Stranded RNA Synthesis Are Made in Viroplasms. J. Virol. 78: 7763-7774 [Abstract] [Full Text]  
  • Sanchez-Fauquier, A., Wilhelmi, I., Colomina, J., Cubero, E., Roman, E. (2004). Diversity of Group A Human Rotavirus Types Circulating over a 4-Year Period in Madrid, Spain. J. Clin. Microbiol. 42: 1609-1613 [Abstract] [Full Text]  
  • Perez Mato, S., Perrin, K., Scardino, D., Begue, R. E. (2002). Evaluation of Rotavirus Vaccine Effectiveness in a Pediatric Group Practice. Am J Epidemiol 156: 1049-1055 [Abstract] [Full Text]  
  • Graff, J. W., Mitzel, D. N., Weisend, C. M., Flenniken, M. L., Hardy, M. E. (2002). Interferon Regulatory Factor 3 Is a Cellular Partner of Rotavirus NSP1. J. Virol. 76: 9545-9550 [Abstract] [Full Text]  
  • Coluchi, N., Munford, V., Manzur, J., Vazquez, C., Escobar, M., Weber, E., Marmol, P., Racz, M. L. (2002). Detection, Subgroup Specificity, and Genotype Diversity of Rotavirus Strains in Children with Acute Diarrhea in Paraguay. J. Clin. Microbiol. 40: 1709-1714 [Abstract] [Full Text]  
  • Cunliffe, N. A., Gondwe, J. S., Graham, S. M., Thindwa, B. D. M., Dove, W., Broadhead, R. L., Molyneux, M. E., Hart, C. A. (2001). Rotavirus Strain Diversity in Blantyre, Malawi, from 1997 to 1999. J. Clin. Microbiol. 39: 836-843 [Abstract] [Full Text]  
  • Gault, E., Chikhi-Brachet, R., Delon, S., Schnepf, N., Albiges, L., Grimprel, E., Girardet, J.-P., Begue, P., Garbarg-Chenon, A. (1999). Distribution of Human Rotavirus G Types Circulating in Paris, France, during the 1997-1998 Epidemic: High Prevalence of Type G4. J. Clin. Microbiol. 37: 2373-2375 [Abstract] [Full Text]  
  • Committee on Infectious Diseases, (1998). Prevention of Rotavirus Disease: Guidelines for Use of Rotavirus Vaccine. Pediatrics 102: 1483-1491 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»